Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

Background. Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods. Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired pneumonia (HAP) due to gram-positive pathogens, particularly methicillin-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinstein, Ethan, Lalani, Tahaniyat, Corey, G. Ralph, Kanafani, Zeina A., Nannini, Esteban C., Rocha, Marcelo G., Rahav, Galia, Niederman, Michael S., Kollef, Marin H., Shorr, Andrew F., Lee, Patrick C., Lentnek, Arnold L., Luna, Carlos M., Fagon, Jean-Yves, Torres, Antoni, Kitt, Michael M., Genter, Fredric C., Barriere, Steven L., Friedland, H. David, Stryjewski, Martin E.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060890/
https://www.ncbi.nlm.nih.gov/pubmed/21148517
http://dx.doi.org/10.1093/cid/ciq031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060890/
https://www.ncbi.nlm.nih.gov/pubmed/21148517
http://dx.doi.org/10.1093/cid/ciq031

Ejemplares similares